- Gross quarterly revenue of $9
million is 18% higher than the previous quarter and 15%
higher than the same period in 2023
- Fiscal Q1/24 marks ninth consecutive quarter generating
positive net income and earnings per share
- Adjusted EBITDA1 in fiscal Q1/24 exceeded
$1.1 million, a 16% increase over
fiscal Q1/23
CALGARY,
AB, Jan. 2, 2024 /CNW/ - CanadaBis Capital
Inc. (the "Company" or "CanadaBis") (TSXV: CANB), a premium
vertically integrated Canadian cannabis company, is pleased to
announce our first quarter fiscal 2024 results featuring another
consecutive period of growth in gross and net revenue. The
Company's Financial Statements and Notes, as well as Management's
Discussion and Analysis ("MD&A") are available on our website
and filed on SEDAR at www.sedar.com.
This quarter reflects another period generating positive
earnings and robust Adjusted EBITDA1, driven by a 45%
increase in unit sales of combined concentrate and dry flower over
the same period the prior year. Stigma Grow also continues to
re-formulate concentrate lines to meet demands from current clients
to maintain larger terpene and cannabinoid profiles across our
product offering. With this ongoing innovation, coupled with demand
for our award-winning Infused Pre-rolls, Live Rosin vapes and high
CBD cartridges, CanadaBis anticipates continued positive
performance in fiscal 2024.
"Building on the momentum realized in fiscal 2023, I am proud to
report that our first fiscal quarter of 2024 represents another
period of growing gross and net revenue," said Travis McIntyre, CEO of CanadaBis. "Our unique
capabilities and consumer-centric value proposition have earned
brand loyalty and positioned CanadaBis to leverage the extracts
segment while introducing additional innovative products such as
our latest offering, the Super Slim Cigarette Style Pre-Rolls -
Electric Dartz. By further optimizing operational efficiencies,
exercising prudent financial management, and maintaining our
competitive edge in the cannabis industry, we believe the Company
is well positioned to drive continued shareholder value
creation."
Q1 2024 HIGHLIGHTS
- Consistent Positive Sales — Gross revenue of
$9.0 million grew 15% over the same
period in 2023 and 18% over the previous quarter, while net revenue
of $5.7 million was 12% and 20%
higher than Q1/23 and Q4/23, respectively. This performance was
driven by steady growth and continued demand for newly launched and
existing SKUs, as sales of over 550,000 units of combined
concentrate and dry flower in Q1/24 reflects a 45% increase
compared to 380,000 units sold in Q1/23.
- Continued Profitability — Net income generated during
Q1/24 totaled $707,117 after tax, or
$0.01 per share, compared to
$700,313 during the same period in
2023, reflecting the impact of additional staff levels that align
with revenue and production increases, along with enhanced
advertising and promotional activities designed to foster demand in
light of increased competition in the infused pre-roll market.
- Adjusted EBITDA1 Contributing to
Performance - Adjusted EBITDA1 totaled over
$1.1 million for Q1/24 and reflects
an increase of 16% over the same period the prior year, largely
attributable to enhanced brand awareness, ongoing expansion of the
Dab Bod products and the launch of the High Priestess brand, along
with multiple new Dab Bod Brand SKUs introduced into the
marketplace.
- New Products Drive Demand — All new products launched
during previous quarters have continued to post growth and record
sales in Alberta, British Columbia, Manitoba, Saskatchewan and Ontario, including our newest and
first-of-its-kind product line, Super Slim Cigarette Style
Pre-Rolls, the "Electric Dartz", which have received solid adoption
across the provinces.
- Cost Management in Focus — The Company has actively
managed input expenses and inflationary pressures through
negotiations and economies of scale, securing cost savings while
increasing operational efficiencies and expanding yields in
cultivation and extraction. We continue to maintain our cost
management plans, along with a focus on increasing efficiencies,
cash flow and liquidity.
QUARTERLY HIGHLIGHTS
Three months ended
October 31
|
|
2023
|
2022
|
% Change
|
Gross
revenue
|
$
9,004,793
|
$ 7,812,425
|
15 %
|
Excise duty
|
$
3,261,402
|
$ 2,664,738
|
22 %
|
Net revenues
|
$
5,743,391
|
$ 5,147,687
|
12 %
|
Cost of
sales
|
$
3,114,741
|
$ 2,783,725
|
12 %
|
Gross profit
|
$
2,628,650
|
$ 2,363,962
|
11 %
|
Net income and
comprehensive income
|
$
707,117
|
$ 700,313
|
1 %
|
Per share (basic and
diluted)
|
$
0.01
|
$ 0.01
|
-
|
Adjusted
EBITDA1
|
$
1,120,920
|
$ 967,178
|
16 %
|
|
|
|
|
|
OUTLOOK
With the continued year-over-year growth in gross and net
revenue, net income, Adjusted EBITDA1 and rigorous cost
controls delivered to date in Q1/24, CanadaBis has set the stage to
deliver another year of strong results. We will strive to
capitalize on our thriving extracts segment, while effectively
navigating a competitive and dynamic climate inherent within the
cannabis industry.
The Company has established several competitive advantages to
ensure long-term success, including our butane hydrocarbon (BHO)
extraction process, and we continue to explore new formulations
that can meet demand and support the diversification of our product
offerings. Rising demand from Alberta, Ontario, and British
Columbia increased sales of resin and shatter infused
pre-rolls and moonrocks, while Dab Bod and High Priestess products
continue to attract greater market share.
As a vertically integrated cannabis company, we bring unique
insights and the ability to respond swiftly to external factors
that may impact selling prices, input costs or shifting customer
demands. With an unwavering commitment to stringent and strategic
capital management, we intend to leverage the extensive CanadaBis
brand portfolio, excellent brand recognition, distinctive products
and strategic resource allocation to further develop innovative
products that optimally align with consumer preferences.
We remain dedicated to advancing success and exploring new
opportunities through 2024 while continuing to prioritize
shareholder value creation. The CanadaBis roadmap remains clear:
actively pursue growth opportunities, stay agile and
well-positioned to react within a volatile cannabis market and
consistently strive to improve operational standards. We look
forward to providing further updates on our progress and success
during the upcoming fiscal year, and appreciate the support of our
shareholders, Board of Directors and employees.
1
|
Adjusted EBITDA is a
Non-GAAP performance measure. Refer to "Advisories - Non-GAAP
Measures" for further details.
|
ABOUT CANADABIS CAPITAL INC.
CanadaBis Capital Inc. (TSXV:CANB) is a vertically integrated
Canadian cannabis company focused on achieving large-scale growth,
from cultivation to retail, in the fast-emerging global cannabis
market. By targeting organic growth opportunities alongside the
right-fit partners, we remain focused on finding and capitalizing
on chances to grow, diversify and continue to lead our
industry.
Our integrated subsidiaries:
- Stigma Pharmaceuticals Inc. – 100% held
- 1998643 Alberta Ltd. (operating as "Stigma Grow") - 100%
held; www.stigmagrow.ca
- Full Spectrum Labs Ltd. (operating as "Stigma Roots") -
100% held
- 2103157 Alberta Ltd. (operating as "INDICAtive
Collection") -100% held; www.indicativecollection.ca
- Goldstream Cannabis Inc. - 95% held
ABOUT STIGMA GROW
Stigma Grow is a cutting-edge cannabis cultivation and
extraction company positioned advantageously to meet the unmet
market demands and stigmas within the legal cannabis industry head
on, with products designed to disturb the status quo and
dramatically shift the conversation surrounding Canada's legal cannabis industry.
CAUTIONARY STATEMENTS
Non-GAAP Measures
This news release contains the financial performance metric of
Adjusted EBITDA, a measure that is not recognized or defined under
IFRS (a "Non-GAAP Measure"). As a result, this data may not be
comparable to data presented by other cannabis companies. For an
explanation and reconciliation of Adjusted EBITDA to related
comparable financial information presented in the Financial
Statements prepared in accordance with IFRS, refer to the MD&A
for the three months ended October 31,
2023. The Company believes that Adjusted EBITDA is a useful
indicator of operational performance and is specifically used by
management to assess the financial and operational performance of
the Company.
Adjusted EBITDA is a measure of the Company's financial
performance. It is intended to provide a proxy for the Company's
operating cash flow and is widely used by industry analysts to
compare CanadaBis to its competitors and derive expectations of
future financial performance of the Company. Adjusted EBITDA
increases comparability between comparative companies by
eliminating variability resulting from differences in capital
structures, management decisions related to resource allocation,
and the impact of fair value adjustments on biological assets,
inventory, and financial instruments, which may be volatile on a
period-to-period basis. Adjusted EBTIDA is not a recognized,
defined, or standardized measure under IFRS. The Company calculates
Adjusted EBITDA as net income (loss) and comprehensive income
(loss) excluding changes in fair value of biological assets, change
in fair value of biological assets realized through inventory sold,
depreciation and amortization expense, share-based payments, and
finance costs.
Regarding Forward-Looking Information
This news release includes certain "forward-looking statements"
under applicable Canadian securities legislation. Forward-looking
statements include but are not limited to statements with respect
to our business and operations; timing of the Sundial products
coming to market; the demand and market for live-resin vape
cartridges, and our general business plans. Forward-looking
statements are necessarily based upon a number of assumptions
including: the ability of the Company's products to compete with
the pricing and product availability on the black-market; the
market demand for the Company's products; and assumptions
concerning the Company's competitive advantages. These assumptions,
while considered reasonable, are subject to known and unknown
risks, uncertainties, and other factors which may cause actual
results and future events to differ materially from those expressed
or implied by such forward-looking statements. Such factors
include, but are not limited to: compliance with extensive
government regulation, the general business, economic, competitive,
political and social uncertainties; ability to sustain or create a
demand for a product; requirement for further capital; delay or
failure to receive board, shareholder or regulatory approvals; the
results of operations and such other matters as set out in the
Company's continuous disclosure on SEDAR at www.sedar.com. There
can be no assurance that such statements will prove to be accurate,
as actual results and future events could differ materially from
those anticipated in such statements.
Accordingly, readers should not place undue reliance on
forward-looking statements. Investors are cautioned that
forward-looking information is not based on historical facts but
instead reflects management's expectations, estimates or
projections concerning future results or events based on the
opinions, assumptions and estimates of management considered
reasonable at the date the statements are made. Although we believe
that the expectations reflected in such forward-looking information
are reasonable, such information involves risks and uncertainties,
and undue reliance should not be placed on such information, as
unknown or unpredictable factors could have a material adverse
effect on our future results, performance or achievements.
Should one or more of these risks or uncertainties materialize,
or should assumptions underlying the forward-looking information
prove incorrect, actual results may vary materially from those
described herein as intended, planned, anticipated, believed,
estimated or expected. Although the Company has attempted to
identify important risks, uncertainties and factors which could
cause actual results to differ materially, there may be others that
cause results not to be as anticipated, estimated or intended. The
Company does not intend, and does not assume any obligation, to
update this forward-looking information except as otherwise
required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE CanadaBis Capital Inc.